Combination chemotherapy: rationale for schedule selection and use of agents with independent toxicities in phase I and II clinical trials.
D000208:Acute Disease / Q000188:drug therapy; D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced; D001500:BCG Vaccine; D001761:Bleomycin / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use*; D006801:Humans; D007165:Immunosuppression Therapy; D007938:Leukemia / Q000188:drug therapy; D008231:Lymphopenia / Q000139:chemically induced; D008938:Mitosis / Q000187:drug effects; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects; D011241:Prednisone / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced; D014750:Vincristine / Q000627:therapeutic use
D001500:BCG Vaccine; D004338:Drug Combinations; D009588:Nitrogen Mustard Compounds; D003561:Cytarabine; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D011241:Prednisone